For a long time the options for lowering cholesterol were a statin, ezetimibe, or little else. Two newer treatments have changed that: inclisiran, an injection given twice a year after the first doses, and bempedoic acid, a tablet designed to avoid the muscle problems some people get with statins. Both are for specific situations rather than general use.
Inclisiran
A different mechanism from anything that came before.
Inclisiran is a small interfering RNA - it works inside liver cells to reduce production of PCSK9, a protein that destroys LDL receptors. With less PCSK9, more receptors survive, and more LDL cholesterol is cleared from the blood.
The practical consequence is the dosing schedule: an initial injection, another after three months, then every six months thereafter.
Twice-yearly dosing is a substantial advantage for anyone who struggles to take a daily tablet, because adherence stops being a daily decision.
It is given by a healthcare professional, usually at the GP practice.
See evolocumab.
Who inclisiran is for
It is not a first-line treatment.
NHS use is generally for people who have already had a cardiovascular event - a heart attack, stroke or similar - whose LDL cholesterol remains above a defined level despite maximum tolerated cholesterol-lowering treatment, or who cannot tolerate statins.
It is used alongside a statin where one is tolerated, and alone or with ezetimibe where not.
Exact eligibility follows NICE guidance and local commissioning, so the answer varies - ask which criteria apply to you.
Side effects are generally mild and mostly reactions at the injection site.
One honest caveat: it has been shown to lower cholesterol substantially, and the long-term outcome data confirming reduced heart attacks and strokes is still accumulating.
See who decides what you can be prescribed.
Bempedoic acid
A tablet, usually taken once daily, frequently as a combination product with ezetimibe.
Its design is the interesting part. It works on the same pathway as statins but is a prodrug activated by an enzyme found in the liver and not in muscle - so in principle it lowers cholesterol without the muscle effects that lead some people to stop statins.
It is used for people who cannot tolerate statins, or in addition where a statin alone is not enough.
Bempedoic acid side effects
Two worth knowing about specifically, because they are not what people expect.
Raised uric acid and gout. Bempedoic acid raises uric acid levels, and gout attacks are more common on it. Tell your prescriber if you have had gout, and report a hot, swollen, painful joint.
Tendon problems. Tendon rupture has been reported, most often affecting the shoulder, biceps or Achilles. Risk is higher in older people, in kidney impairment, and alongside corticosteroids or fluoroquinolone antibiotics. Report tendon pain or swelling and rest the limb.
Also reported: raised liver enzymes, and anaemia.
See medicines, muscles and joints and allopurinol.
Where they fit
The usual sequence is a statin first, at the highest tolerated dose, because statins have the largest and best-established outcome evidence.
Ezetimibe is added if the target is not reached.
Then, depending on eligibility, inclisiran, a PCSK9 inhibitor, or bempedoic acid.
Before concluding a statin cannot be tolerated, it is worth working through the usual checks - whether an untreated thyroid problem is causing the aches, whether an interacting medicine is raising statin levels, and whether a different statin at a lower dose or alternate-day dosing would work. A supervised trial off and back on frequently shows the statin was not responsible.
See statins and muscle pain and pravastatin.
Cost and access
Both are considerably more expensive than a statin, which is why eligibility is defined narrowly.
That does not change what you pay - the prescription charge is a flat fee per item regardless of cost, and nothing if you are exempt. It does explain why a request may be declined at the formulary stage even where a specialist thinks it reasonable, and why asking which gate a refusal came from is the useful question. See what you are actually paying for.
What to report
Both are relatively new, and reporting matters more for newer medicines because the safety picture is still filling in.
Report tendon pain, gout attacks, muscle symptoms, injection site problems or anything unexpected through the Yellow Card scheme as well as to your prescriber. See black triangle medicines.
Practical points
Neither is a substitute for the rest of cardiovascular risk management - blood pressure, smoking, weight and diabetes control all still matter.
Both are stopped in pregnancy, and effective contraception is needed.
Cholesterol is rechecked after starting to confirm the response.
Make sure these appear on your medicines list - a twice-yearly injection is exactly the sort of thing people forget to mention, and a specialist-administered treatment may not reach every record.
Related reading: Familial Hypercholesterolaemia, with more on how the main families of medicine work in Medicines.